Treatment and prevention of the common cold using povidone-iodine
The present invention provides a method of treating and preventing the common cold and associated secondary illnesses in a human subject, when the common cold is caused by viruses. The method comprises applying to the nasal passages of the human subject at ambient temperature, an effective amount of a pharmaceutical preparation comprising povidone-iodine (PVP-I) at a concentration of greater than 0.10% w/v and less than 2.5% in which at least 50% of the PVP-I is not associated with liposomes or other particulate carriers.
1. A method of treating the common cold in a human subject in need thereof, the method comprising applying to the nasal passages of the human subject at ambient temperature of between 10° C. to 30° C., an effective amount of a pharmaceutical preparation comprising povidone-iodine (PVP-I) at a concentration of greater than 0.10% w/v and less than about 1.25% w/v and in which at least 50% of the PVP-I is not associated with liposomes or other particulate carriers and wherein the causative agent of the common cold is a virus selected from the group consisting of rhinoviruses, human coronaviruses, human parainfluenza viruses, human respiratory syncytial viruses, adenoviruses, enteroviruses other than rhinoviruses, metapneumoviruses, and any combinations thereof.
2. The method according to claim 1 , wherein the PVP-I concentration in the pharmaceutical preparation applied to the nasal passages is 0.1% to about 1.0% w/v.
3. The method according to claim 2 , wherein the PVP-I concentration in the pharmaceutical preparation applied to the nasal passages is about 0.2% to about 0.45% w/v.
4. The method according to claim 1 , wherein the pharmaceutical preparation does not contain liposomes.
5. The method according to claim 1 , wherein the pharmaceutical preparation is administered into the nostrils of the human subject, between 1 and 12 times daily.
6. The method according to claim 1 , wherein the causative agent of the common cold is a rhinovirus.
7. A method of reducing the symptoms of the common cold in a human subject in need thereof, the method comprising applying to the nasal passages of the human subject at ambient temperature of between 10° C. to 30° C., an effective amount of a pharmaceutical preparation comprising povidone-iodine (PVP-I) at a concentration of greater than 0.10% w/v and less than about 2.5% w/v and in which at least 50% of the PVP-I is not associated with liposomes or other particulate carriers and wherein the causative agent of the common cold is a virus selected from the group consisting of rhinoviruses, human coronaviruses, human parainfluenza viruses, human respiratory syncytial viruses, adenoviruses, enteroviruses other than rhinoviruses, metapneumoviruses, and any combinations thereof.
8. The method according to claim 7 , wherein the PVP-I concentration in the pharmaceutical preparation applied to the nasal passages is 0.1% to about 1.0% w/v.
9. The method according to claim 8 , wherein the PVP-I concentration in the pharmaceutical preparation applied to the nasal passages is about 0.2% to about 0.45% w/v.
10. The method according to claim 7 , wherein the pharmaceutical preparation does not contain liposomes.
11. The method according to claim 7 , wherein the pharmaceutical preparation is administered into the nostrils of the human subject, between 1 and 12 times daily.
12. The method according to claim 7 , wherein the causative agent of the common cold is a rhinovirus.
13. The method according to claim 7 where the common cold symptom is selected from the group consisting of chills, headaches, aches and pain, tiredness, running nose, sneezing, cough, nasal congestion, sore throat and combinations thereof.
14. A method of reducing the activity, viability or number of viruses within the nasal passages of a human subject in need thereof, wherein the viruses are causative agents of the common cold, the method comprising applying to the nasal passages of the human subject at ambient temperature of between 10° C. to 30° C., an effective amount of a pharmaceutical preparation comprising povidone-iodine (PVP-I) at a concentration of greater than 0.10% w/v and less than about 2.5% w/v and in which at least 50% of the PVP-I is not associated with liposomes or other particulate carriers, wherein the virus selected from the group consisting of rhinoviruses, human coronaviruses, human parainfluenza viruses, human respiratory syncytial viruses, adenoviruses, enteroviruses other than rhinoviruses, metapneumoviruses, and any combinations thereof.
15. The method according to claim 14 , wherein the PVP-I concentration in the pharmaceutical preparation applied to the nasal passages is 0.1% to about 1.0% w/v.
16. The method according to claim 15 , wherein the PVP-I concentration in the pharmaceutical preparation applied to the nasal passages is about 0.2% to about 0.45% w/v.
17. The method according to claim 14 , wherein the pharmaceutical preparation does not contain liposomes.
18. The method according to claim 14 , wherein the pharmaceutical preparation is administered into the nostrils of the human subject, between 1 and 12 times daily.
19. The method according to claim 14 , wherein the virus is a rhinovirus.